KYMR Q3 EPS Increased by Brookline Capital Management

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Stock analysts at Brookline Capital Management upped their Q3 2025 EPS estimates for Kymera Therapeutics in a report released on Monday, August 11th. Brookline Capital Management analyst L. Cann now anticipates that the company will earn ($0.86) per share for the quarter, up from their previous estimate of ($0.92). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics’ Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($3.24) EPS, FY2026 earnings at ($4.31) EPS, FY2027 earnings at ($4.76) EPS, FY2028 earnings at ($5.69) EPS and FY2029 earnings at ($5.13) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The company had revenue of $11.48 million for the quarter, compared to analyst estimates of $17.37 million. During the same quarter in the prior year, the company posted ($0.58) EPS. Kymera Therapeutics’s revenue for the quarter was down 55.1% on a year-over-year basis.

Several other brokerages have also weighed in on KYMR. JPMorgan Chase & Co. upped their price objective on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the company an “overweight” rating in a report on Tuesday, June 3rd. Stifel Nicolaus started coverage on shares of Kymera Therapeutics in a research report on Tuesday, May 20th. They issued a “buy” rating and a $55.00 price target on the stock. Jefferies Financial Group set a $64.00 price target on shares of Kymera Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 25th. UBS Group dropped their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target (up previously from $54.00) on shares of Kymera Therapeutics in a research report on Thursday, June 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $59.11.

Kymera Therapeutics Trading Up 2.6%

Shares of NASDAQ KYMR opened at $42.63 on Thursday. The firm’s 50-day moving average price is $44.64 and its 200-day moving average price is $36.49. Kymera Therapeutics has a 1-year low of $19.44 and a 1-year high of $53.27. The firm has a market capitalization of $3.05 billion, a P/E ratio of -12.29 and a beta of 2.18.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Elena Ridloff sold 12,000 shares of the company’s stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a total value of $553,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the transaction, the chief executive officer directly owned 660,482 shares of the company’s stock, valued at $32,363,618. This represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,349 shares of company stock worth $2,334,301 in the last ninety days. 16.01% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC grew its position in shares of Kymera Therapeutics by 642.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after acquiring an additional 540 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares during the period. State of Wyoming bought a new position in shares of Kymera Therapeutics during the 4th quarter valued at approximately $45,000. GF Fund Management CO. LTD. bought a new position in shares of Kymera Therapeutics during the 4th quarter valued at approximately $55,000. Finally, Raymond James Financial Inc. bought a new position in shares of Kymera Therapeutics during the 2nd quarter valued at approximately $73,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.